Founding Partner
According to Healthline.com, injectable medications Ozempic and Wegovy (active ingredient semaglutide) and Mounjaro (active ingredient tirzepatide), work by slowing down digestion in the stomach. In some instances, this delay in stomach emptying, known as gastroparesis (or “stomach paralysis”) , can occur.
The United States Food & Drug Administration (FDA) has been receiving reports of gastroparesis with semaglutide and liraglutide, with some documenting that the adverse event was unresolved even after the product was discontinued at the time of reporting.
Physicians who specialize in gastroparesis treatment say they are also hearing more reports of gastroparesis as an increasing number of people use these medications.
Parker Waichman LLP understands the challenges faced by individuals who have experienced adverse effects after being prescribed Ozempic. If you or a loved one have suffered from any of the following side effects and injuries associated with Ozempic usage, including gastroparesis, gastroenteritis, delayed gastric emptying, recommended intestinal surgery, pancreatic cancer, intraoperative pulmonary aspiration, deep vein thrombosis, or pulmonary aspiration, our national product liability law firm is here to help. We are offering a free consultation to discuss your legal options and potential compensation for your suffering.
Our experienced attorneys are dedicated to advocating for the rights of individuals harmed by dangerous pharmaceuticals. We will carefully evaluate your case, provide personalized legal guidance, and pursue justice on your behalf.
Don’t hesitate to reach out to us to schedule your free consultation and take the first step towards seeking the compensation you deserve. For your free consultation, contact our national product liability law firm today by using our live chat or calling 800-968-7529.
On March 28, 2022, Novo Nordisk announced the FDA’s approval of a higher (2 mg) dose of the Ozempic (semaglutide) injection. In the press release, the drug maker represented Ozempic as having “proven safety and efficacy” and further advertised that ” it can help many patients lose some weight.” However, severe gastrointestinal events, such as gastroparesis and gastroenteritis, were not identified as risks.
Similarly, on May 13, 2022, Eli Lilly announced FDA approval of Mounjaro (tirzepatide), pitched by the drug maker as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes. In the announcement, Eli Lilly disclosed a safety summary, but severe gastrointestinal events were not identified as risks.
Recent studies have linked Ozempic and Wegovy to non-arteritic anterior ischemic optic neuropathy (NAION), a condition that causes permanent vision loss by restricting blood flow to the optic nerve. Patients who took these GLP-1 weight loss and diabetes drugs have reported sudden blindness, optic nerve inflammation, and irreversible damage—life-altering effects that were never properly disclosed by drug manufacturers.
A 2025 JAMA Ophthalmology study revealed that GLP-1 drug users are at a significantly higher risk of developing NAION and other optic nerve disorders. Harvard researchers found that diabetics taking semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss were at a seven times higher risk. Despite this alarming data, Novo Nordisk continues to downplay these risks, failing to provide adequate warnings about the potential for permanent blindness.
In September 2025, the European Medicines Agency (EMA) issued a formal warning that Ozempic, Wegovy, and Rybelsus carry a “very rare but serious” risk of causing non-arteritic anterior ischemic optic neuropathy (NAION). NAION is a devastating condition that can lead to irreversible vision loss.
According to the EMA’s updated regulatory language:
“Data from epidemiological studies indicates an increased risk for non-arteritic anterior ischaemic optic neuropathy (NAION) during treatment with semaglutide. There is no identified time interval for when NAION may develop following treatment start. A sudden loss of vision should lead to ophthalmological examination, and treatment with semaglutide should be discontinued if NAION is confirmed.”
This language is now included in the Summary of Product Characteristics (SmPC) and Package Leaflet, formalizing NAION as an adverse event of concern.
The decision came after months of pharmacovigilance review and mounting evidence, including the 2024 Mass Eye and Ear study and 2025 analyses published in JAMA Ophthalmology. These studies found that semaglutide users face a 4.28-fold increased risk of NAION in diabetic patients and a 7.64-fold increased risk in patients using the drugs for weight loss.
Despite the data, U.S. regulators have not issued a comparable warning, leaving American patients at risk. “People trusted that these medications were safe for use,” said Jason Goldstein, Senior Litigation Counsel at Parker Waichman LLP. “This new EMA confirmation underscores what we have been seeing through our clients’ experiences—sudden, devastating loss of vision that changes lives forever.”
Parker Waichman LLP is currently representing patients across the United States who have experienced sudden vision loss, permanent blindness, or non‑arteritic anterior ischemic optic neuropathy (NAION) after using semaglutide medications such as Ozempic, Wegovy, or Rybelsus. Our law firm is actively filing claims across the nation on behalf of individuals who trusted these medications to manage diabetes or assist with weight loss, only to suffer irreversible eye injuries that dramatically altered their lives.
Our legal team is working closely with medical experts, ophthalmologists, and pharmacovigilance specialists to uncover what Novo Nordisk knew about these risks and when the company first became aware of the connection between semaglutide and optic nerve damage. We are pursuing justice for victims whose lives have been disrupted by loss of sight, ensuring that corporate accountability and patient safety remain front and center in this developing litigation.
Victims suffering from vision loss after using Ozempic, Wegovy, or similar medications, may have grounds to file a product liability lawsuit against the manufacturers. These lawsuits allege that drug companies failed to warn users about the risk of optic nerve damage—a serious omission that has left unsuspecting patients with irreversible blindness.
Compensation may cover:
Parker Waichman LLP is actively investigating GLP-1 drug-related blindness cases and is prepared to fight for victims who have suffered devastating, life-changing harm.
If you or a loved one lost vision after using Ozempic or Wegovy, you may be entitled to financial compensation. Call 800-968-7529 today for a free consultation with our defective drug lawyers and find out how Parker Waichman LLP can help you hold drug manufacturers accountable.
Parker Waichman LLP
If you or a loved one has been injured in an accident or have been injured by another party in some other way, we are here to stand up for your rights. Our personal injury attorneys have been representing injury victims and their families in Long Island and throughout the nation since the early 1980s.
Our law firm is ready to represent you in your injury case. We’ve helped many New York residents as well as those needing help nationwide. Contact our team for a free case consultation today.
I had a great experience with them , everyone was very helpful and sweet.
Michelle Murphy
4 months ago
Zarahi was very professional and very Quick and very knowledgeable i realy appreciated her patience and perseverance she Deserves 100 stars 🌟 but since i can only send 5 i Guess i will just have to send that truly yours Rashine Downs
Kush Three
6 months ago
VERY NICE WORK PLACE THEY HAVE BEEN GOOD TO MY MOM
Whitney Brinson
5 years ago
They treated me with tender love and care
Terrell Weaver
2 months ago
Wonderful people. They made the whole process if dealing with a gov’t agency so easy. Special compliments to Gina Viti
Michael Ross
2 months ago
I’m a 9/11 first responder, and I can honestly say that Parker Waichman made me feel like they had my best interest in my VCF case. Ms Candalino & Ms Viti are top notch in my book. I was constantly informed on the status of my case. I would definitely recommend Parker Waichman LLP to family and friends.
D D
6 years ago
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
Parker Waichman LLP
27299 Riverview Center Boulevard, Suite 108
Bonita Springs, FL 34134
We handle mass torts cases nationwide. Please contact our office to learn more.